How India is leading a cancer revolution

Описание: You probably can't afford this cancer therapy.

CAR-T is a form of immunotherapy that shows incredible promise in offering a cure to blood cancers that are resistant to standard treatment. Unfortunately, it remains out of reach to the vast majority of the world due to its high price point.

But thanks to Indian start-up ImmunoAct, that price point is about to change.

SOURCE LIST:

National Cancer Institute. (2025, February 26). CAR T cells: Engineering patients’ immune cells to treat their cancers. U.S. Department of Health and Human Services. https://www.cancer.gov/about-cancer/t...

BioSpace. (n.d.). CAR-T cell therapy market size worth USD 128.55 billion by 2034. https://www.biospace.com/press-releas...

Winstead, E. (2017, September 11). CAR T-cell therapy approved for some children and young adults with leukemia. National Cancer Institute, U.S. Department of Health and Human Services. https://www.cancer.gov/news-events/ca...

Herper, M. (2017, August 30). Novartis CEO’s dilemma: Is $475,000 too much for a leukemia breakthrough—or is it not enough? Forbes. https://www.forbes.com/sites/matthewh...

Macrotrends. (n.d.). India healthcare spending 2000–2025. https://www.macrotrends.net/global-me...

Novartis. (n.d.). The process of CAR-T cell therapy. https://www.novartis.com/research-and...

Pharmaceutical Technology. (n.d.). CAR‑T cell therapy cost: Japan approves Novartis’ Kymriah (tisagenlecleucel). https://www.pharmaceutical-technology...

Mallapaty, S. (2024, March 21). Cutting‑edge CAR‑T cancer therapy is now made in India — at one‑tenth the cost. Nature. https://doi.org/10.1038/d41586‑024‑00...

Wang, L. (2024, February 7). India’s first homegrown CAR T‑cell therapy has roots in NCI collaboration. National Cancer Institute, U.S. Department of Health and Human Services. https://www.cancer.gov/news-events/ca...

Andrade, C., Shah, N., & Chandra, S. (2007). The new patent regime: Implications for patients in India. Indian Journal of Psychiatry, 49(1), 56–59. https://www.ncbi.nlm.nih.gov/pmc/arti...

The Economic Times. (2023, July 25). India produces over 60,000 generic drugs, highlights MoS Bhagwant Khuba. https://www.economictimes.indiatimes....

Ojha, S. (2024, December 5). India’s pharma future relies on regulatory strength. BioProcess International. https://www.bioprocessintl.com/therap...

Gee, A. P. (2018). GMP CAR‑T cell production. Best Practice & Research Clinical Haematology, 31(2), 126–134. https://doi.org/10.1016/j.beha.2018.0...

Pant, B., Goda, J., & Gota, V. (2024). Drug development in LMICs: Could the emerging Indian model usher the Southeast Asian region? The Lancet Regional Health – Southeast Asia, 29, 100464. https://doi.org/10.1016/j.lansea.2024...

Menichiello, T. (2024, January 22). Paving the way for India’s first domestic CAR‑T approval. Cell & Gene. https://www.cellandgene.com/doc/pavin...

Onyx Newsroom: https://www.onyxnewsroom.com/

Special thanks to the ImmunoAct team for offering guidance and insight.

Get in touch: sameed@onyxnewsroom